Pharma Stocks Under Pressure on US Tariff Concerns

Key Developments • US proposed 100% tariff on branded/patented pharma imports (effective Oct 2025) • Fresh reports suggest further escalation in policy stance • Section 232 investigation into pharma imports adds regulatory overhang Market Reaction • Sun Pharma stock fell ~4% despite limited direct exposure • Broader pharma stocks also saw sentiment-driven selling What’s the Real Risk? • Indian companies largely export generics (currently outside tariff scope) • Key concern: possible future extension of tariffs to generics • India supplies ~47% of US generic drug demand, making this a major risk if policy expands Why It Matters Even without immediate impact, companies with high US exposure may see valuation pressure due to uncertainty and policy risk. Learning Outcome Markets often react to future risks, not just current impact. Investors should distinguish between sentiment-driven corrections and actual fundamental changes.